Literature DB >> 8686737

The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.

J Keleti1, M M Quezado, M M Abaza, M Raffeld, M Tsokos.   

Abstract

MDM2 gene overexpression has been implicated in the pathogenesis of human neoplasia via inhibition of the p53 tumor-suppressor function. To investigate the potential involvement of the MDM2 oncogene in the pathogenesis of childhood rhabdomyosarcoma (RMS) we studied MDM2 abnormalities in six RMS cell lines in correlation with the p53 status. Three showed overexpression of MDM2 mRNA and protein, one with concomitant MDM2 gene amplification. All three lacked p53 mutation and expressed low levels of p53 mRNA but exhibited elevated p53 proteins. Double immunostaining revealed that the overexpressed MDM2 and p53 proteins were co-localized to the same cell nuclei. Furthermore, the two proteins were physically associated, as shown by co-immunoprecipitation and Western blot analysis. The half-life of the p53 protein was prolonged in the MDM2-expressing RMS cells. The extended half-life wildtype p53 protein and its complex formation with the elevated MDM2 suggest that the underlying mechanism for p53 protein accumulation in these cell lines is p53 stabilization by an overabundant MDM2 protein. The overexpressed MDM2 protein had a short half-life. The three remaining RMS cell lines exhibited low MDM2 mRNA and protein levels and carried p53 mutations. This study suggest that MDM2 overexpression represents an alternative mechanism for p53 inactivation in a subset of childhood RMS without p53 mutations. The results further indicate that the elevated MDM2 protein is responsible for wildtype p53 protein accumulation via stabilization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8686737      PMCID: PMC1865219     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

1.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

2.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Authors:  G Gaidano; P Ballerini; J Z Gong; G Inghirami; A Neri; E W Newcomb; I T Magrath; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

3.  Cultivation in vitro of cells derived from a human rhabdomyosarcoma.

Authors:  R M McAllister; J Melnyk; J Z Finkelstein; E C Adams; M B Gardner
Journal:  Cancer       Date:  1969-09       Impact factor: 6.860

4.  p53 germline mutations in Li-Fraumeni syndrome.

Authors:  M F Santibáñez-Koref; J M Birch; A L Hartley; P H Jones; A W Craft; T Eden; D Crowther; A M Kelsey; M Harris
Journal:  Lancet       Date:  1991-12-14       Impact factor: 79.321

5.  Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma.

Authors:  C A Felix; C C Kappel; T Mitsudomi; M M Nau; M Tsokos; G D Crouch; P D Nisen; N J Winick; L J Helman
Journal:  Cancer Res       Date:  1992-04-15       Impact factor: 12.701

Review 6.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

7.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

8.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.

Authors:  P R Yew; A J Berk
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

9.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

10.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

Authors:  S S Fakharzadeh; S P Trusko; D L George
Journal:  EMBO J       Date:  1991-06       Impact factor: 11.598

View more
  23 in total

Review 1.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

2.  FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Authors:  Lisa E S Crose; Katherine T Etheridge; Candy Chen; Brian Belyea; Lindsay J Talbot; Rex C Bentley; Corinne M Linardic
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

3.  Nutlin-3 down-regulates retinoblastoma protein expression and inhibits muscle cell differentiation.

Authors:  Erica M Walsh; MengMeng Niu; Johann Bergholz; Zhi-Xiong Jim Xiao
Journal:  Biochem Biophys Res Commun       Date:  2015-04-12       Impact factor: 3.575

Review 4.  Developmental origins of fusion-negative rhabdomyosarcomas.

Authors:  Ken Kikuchi; Brian P Rubin; Charles Keller
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

Review 5.  Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Authors:  Venkatesh P Kashi; Mark E Hatley; Rene L Galindo
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

6.  Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.

Authors:  Julie J G Kephart; Rosanne G J Tiller; Lisa E S Crose; Katherine K Slemmons; Po-Han Chen; Ashley R Hinson; Rex C Bentley; Jen-Tsan Ashley Chi; Corinne M Linardic
Journal:  Clin Cancer Res       Date:  2015-06-12       Impact factor: 12.531

7.  PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma.

Authors:  J Anderson; A Ramsay; S Gould; K Pritchard-Jones
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

8.  Epstein-Barr virus infection correlates with the expression of COX-2, p16(INK4A) and p53 in classic Hodgkin lymphoma.

Authors:  Suhail Al-Salam; Aktham Awwad; Manjusha Sudhadevi; Sayel Daoud; Nico J D Nagelkerke; Antonio Castella; S M Chong; Mouied Alashari
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

9.  Effects of RAS on the genesis of embryonal rhabdomyosarcoma.

Authors:  David M Langenau; Matthew D Keefe; Narie Y Storer; Jeffrey R Guyon; Jeffery L Kutok; Xiuning Le; Wolfram Goessling; Donna S Neuberg; Louis M Kunkel; Leonard I Zon
Journal:  Genes Dev       Date:  2007-05-17       Impact factor: 11.361

10.  MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.

Authors:  C Zietz; M Rössle; C Haas; A Sendelhofert; A Hirschmann; M Stürzl; U Löhrs
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.